26 August 2011
A protein added to bone marrow in mice decreases the likelihood of cancerous cells developing, a study from the University of Kentucky has shown.
Investigating the effects of adding the tumour-suppressing protein Par-4 to bone marrow, scientists discovered that transplanting the modified tissue to a control group resulted in expressions of cancer-killing protein activity.
The results, published as a lead article in the Cancer Biology & Therapy journal, suggested the successful transfer of cancer inhibiting proteins "may offer a new approach to treat not only primary tumours but also metastatic tumours of diverse origin," according to lead author Dr Vivek Rangnekar.
Chair of oncology research at the university's Markey Cancer Center, Dr Rangnekar added that he is "excited by the findings of this study" as it offers potentially groundbreaking innovations in cancer treatment.
Meanwhile, a research team at the Intermountain Clinical Genetic Institute have claimed to have developed a new cost-effective system to gauge whether at-risk patients of cancer require full genome sequencing screening, so helping to speed up the rate of cancer diagnosis.
Posted by Edward Bartel
1 Zhao, Yanming, et. al., "Systemic Par-4 inhibits non-autochthonous tumor growth". Cancer Biology and Therapy. Friday July 15th 2011.
2 Gudgeon, James M, et al., "Lynch Syndrome Screening Implementation: Business Analysis by a Healthcare System". American Journal of Managed Care. August 2011.
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.